ITFG2

Across TCGA pan-cancer cohorts, ITFG2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ITFG2 data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ITFG2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ITFG2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, BRCA, and COAD are the cancer types where ITFG2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.266	0.835	<.001	18	view →
BRCA	OS	Median	II,III,IV	0.638	0.958	.020	6	view →
COAD	OS	Median	All	0.181	0.806	.002	6	view →
UCEC	DFS	Median	II,III,IV	1.000	0.443	.036	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ITFG2–LUAD (OS)

Open the LUAD breakdown →